GSK (GSK) – Reuters
-
GSK completes acquisition of Aiolos Bio for up to $1.4 billion
-
GSK sees strong growth as Haleon split and vaccine drive pays off
-
GSK raises $1.24 billion from latest Haleon stake sale
-
GSK boosts respiratory portfolio with $1.4 billion Aiolos Bio deal
-
Pfizer RSV vaccine lags GSK’s as head-to-head competition underway
-
GSK sues Pfizer in US for patent infringement over RSV vaccine
-
US Supreme Court rejects Teva challenge to $235 million GSK award in patent dispute
-
GSK sells partial stake in spin-off firm Haleon at discount
-
Biden admin urges Supreme Court to hear 'skinny labels' case between Teva, GSK
-
US panel backs GSK vaccine, heating up RSV vaccine race
-
GSK, Pfizer, Sanofi fend off thousands of U.S. lawsuits over alleged Zantac cancer link
-
GSK, Sanofi and Haleon shares slump on Zantac litigation concerns
-
GSK measles vaccine gets U.S. FDA approval
-
GSK to spend up to $3.3 billion on Affinivax to boost vaccines roster
-
GSK to name consumer healthcare unit 'Haleon' after spin-off
-
GSK sees sales growth in 2022 after quarterly beat, prepares for spin-off
-
GSK to get $1.25 billion to settle HIV drug patent row with Gilead
-
GSK, Vir ramping up U.S. output of COVID antibody drug
-
Unilever strategy under scrutiny after short-lived GSK skirmish
-
Unilever will not raise rejected 50 billion pound bid for GSK consumer arm
-
Unilever's offer for GSK's consumer health raises doubts, questions over strategy
-
U.S. secures 600,000 more doses of GSK-Vir's COVID-19 therapy
-
Medicago's plant-based vaccine trial shows 75.3% efficacy against Delta variant
-
GSK says tests indicate antibody drug works against Omicron
-
U.S. secures GSK-Vir COVID-19 antibody therapy doses worth $1 billion
-
GSK-Vir COVID-19 antibody works as shot in the arm as well as infusion
-
GSK on track with consumer split as buyout report boosts shares
-
Activist investor Bluebell takes stake in GSK
-
GSK, CureVac's next-gen COVID-19 vaccine shows promise in monkey trial
-
GSK more upbeat on profits and COVID, investors not sure
-
GSK anaemia drug shows promise as treatment in kidney disease patients
-
GSK rejects Elliott's demands for board change, consumer sale
-
GlaxoSmithKline taps Goldman, Citi to advise on consumer unit spinoff - Bloomberg News
-
GSK's drugs arm to get $11 billion booster from consumer spin-off
-
GSK, iTeos to develop cancer drug in up to $2 billion deal
-
Sanofi-GSK report positive interim results for their COVID-19 shot
-
CureVac-GSK coronavirus variant vaccine generates good immune response in rats
-
Lilly-Vir's COVID-19 antibody combo reduces viral load in study
-
GSK warns COVID-19 will dent full-year earnings
-
AstraZeneca shares gain as coronavirus vaccine trials resume
-
U.S., European COVID-19 vaccine developers pledge to uphold testing rigour
-
GSK, partner Vir join race to find COVID-19 antibody treatment
-
Moderna, EU conclude advanced talks to supply COVID-19 vaccine candidate
-
Vaccine makers including Moderna must hit U.S. timing goals for full payments
-
GSK profit misses as vaccine sales disappoint, stockpiling eases
-
Exclusive: EU talks with Pfizer, Sanofi, J&J on COVID vaccines hit snags - sources
-
Exclusive: EU in talks with Moderna, BioNtech, CureVac to secure possible COVID vaccines
-
GSK to develop plant-based COVID-19 vaccine with Canada's Medicago
-
French drugmaker Sanofi to cut up to 1,680 jobs in Europe
-
Exclusive: Sanofi considers job cuts as CEO seeks to reduce costs - sources
Back to GSK Stock Lookup
